MARKET WIRE NEWS

Tourlite Capital Q1 2025 Investor Letter

Source: SeekingAlpha

2025-06-04 02:00:00 ET

Summary

  • Tourlite Fund returned -4.6% in Q1 2025, underperforming the S&P 500, amid market volatility driven by Trump’s tariff agenda and macro uncertainty.
  • We tactically increased net exposure during the quarter, favoring industrials and event-driven longs, while maintaining shorts in consumer discretionary and staples.
  • Key portfolio winners included Sable Offshore, FTAI Infrastructure, and select biotech special situations; shorts in overvalued consumer names also contributed.
  • Despite recent underperformance, I remain confident in our strategy and see compelling opportunities ahead, especially as market dislocations persist.

To My Partners:

Tourlite Fund, LP returned ?4.6% for the First Quarter of 2025. The Fund has annualized returns of 7.5% since inception, compared to 9.0% for the S&P 500 ( SP500 , SPX ) and 0.5% for the Russell 2000 ( RTY ). 1,2 ...

Read the full article on Seeking Alpha

For further details see:

Tourlite Capital Q1 2025 Investor Letter
Arbutus Biopharma Corporation

NASDAQ: ABUS

ABUS Trading

-5.59% G/L:

$4.395 Last:

2,473,568 Volume:

$4.64 Open:

mwn-link-x Ad 300

ABUS Latest News

ABUS Stock Data

$811,607,352
153,282,242
0.14%
53
N/A
Biotechnology & Life Sciences
Healthcare
US
Warminster

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App